ASH 2023 | Low-intensity venetoclax-based salvage as a bridge to alloSCT in AML
Chong Chyn Chua, MBBS, FRACP, FRCPA, The Alfred Hospital and Monash University, Melbourne, Australia, discusses a study investigating low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplantation (alloSCT) in patients with acute myeloid leukemia (AML). This study demonstrates the efficacy and tolerability of this regimen, with patients achieving blast clearance and measurable residual disease (MRD) negativity. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS, Astra Zeneca, AbbVie, Otsuka: Speakers Bureau; AbbVie, Pfizer, Sumitomo Pharma Oncology: Consultancy.
